Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2079194 | 1.00 | ALDH1A1 (0.59) | ALDH1A1KMT2AALOX5GAASMN1; SMN2 | |
| SCHEMBL2772899 | 0.85 | ALOX5 (0.54) | ALDH1A1KMT2AALOX5GAAPOLB | |
| SCHEMBL30865951 | 0.82 | ALOX5 (0.72) | ALDH1A1KMT2AALOX5GAAPOLB | |
| SCHEMBL19995957 | 0.81 | NPC1 (0.56) | ALDH1A1KMT2AALOX5GAASMN1; SMN2 | |
| SCHEMBL20006108 | 0.81 | NPC1 (0.56) | ALDH1A1KMT2AALOX5GAASMN1; SMN2 | |
| SCHEMBL13836513 | 0.81 | ALOX5 (0.72) | ALDH1A1KMT2AALOX5GAAPOLB | |
| SCHEMBL28200535 | 0.78 | HPGD (0.61) | ALDH1A1POLB | |
| SCHEMBL13162572 | 0.76 | ALDH1A1 (0.54) | ALDH1A1KMT2AALOX5SMN1; SMN2POLB | |
| SCHEMBL3435149 | 0.76 | ALDH1A1 (0.54) | ALDH1A1KMT2AALOX5SMN1; SMN2POLB | |
| SCHEMBL2153314 | 0.76 | ALDH1A1 (0.71) | ALDH1A1KMT2AALOX5SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | ALDH1A1 975/4885KMT2A 1707/4885ALOX5 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.